| 1.8 0.3 (20%) | 05-22 15:19 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.33 | 1-year : | 2.72 |
| Resists | First : | 2 | Second : | 2.33 |
| Pivot price | 1.91 |
|||
| Supports | First : | 1.69 |
Second : | 1.5 |
| MAs | MA(5) : | 1.85 |
MA(20) : | 1.91 |
| MA(100) : | 1.26 |
MA(250) : | 2.32 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 60.1 |
D(3) : | 73 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 6.36 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ EGRX ] has closed above bottom band by 15.8%. Bollinger Bands are 49.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.65 - 1.66 | 1.66 - 1.67 |
| Low: | 1.48 - 1.49 | 1.49 - 1.5 |
| Close: | 1.63 - 1.65 | 1.65 - 1.67 |
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Fri, 16 May 2025
Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Thu, 08 May 2025
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com - Defense World
Mon, 31 Mar 2025
Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale - Stock Titan
Fri, 21 Mar 2025
Eagle Pharmaceuticals Doubles Anti-Takeover Protection to $20 in Rights Plan Update - Stock Titan
Fri, 21 Mar 2025
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 13 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 50.6 (%) |
| Shares Short | 351 (K) |
| Shares Short P.Month | 484 (K) |
| EPS | 0.85 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.25 |
| Profit Margin | 4.6 % |
| Operating Margin | 15.9 % |
| Return on Assets (ttm) | 6.6 % |
| Return on Equity (ttm) | 4.8 % |
| Qtrly Rev. Growth | -12.9 % |
| Gross Profit (p.s.) | 13.87 |
| Sales Per Share | 19.87 |
| EBITDA (p.s.) | 4.8 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 38 (M) |
| PE Ratio | 2.11 |
| PEG Ratio | 0 |
| Price to Book value | 0.09 |
| Price to Sales | 0.09 |
| Price to Cash Flow | -2.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|